Schonfeld Strategic Advisors LLC Buys New Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)

Schonfeld Strategic Advisors LLC purchased a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 291,795 shares of the company's stock, valued at approximately $3,218,000. Schonfeld Strategic Advisors LLC owned approximately 0.55% of Stoke Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. KLP Kapitalforvaltning AS acquired a new position in shares of Stoke Therapeutics during the 4th quarter worth approximately $63,000. Teacher Retirement System of Texas acquired a new position in Stoke Therapeutics during the fourth quarter worth $113,000. China Universal Asset Management Co. Ltd. purchased a new stake in Stoke Therapeutics in the 4th quarter valued at $124,000. Tower Research Capital LLC TRC increased its stake in shares of Stoke Therapeutics by 70.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company's stock worth $132,000 after acquiring an additional 4,918 shares during the last quarter. Finally, Invesco Ltd. purchased a new position in shares of Stoke Therapeutics during the 4th quarter worth $133,000.

Stoke Therapeutics Stock Performance

Shares of NASDAQ STOK traded up $0.46 during trading on Friday, reaching $9.51. The stock had a trading volume of 379,908 shares, compared to its average volume of 710,710. The company has a market cap of $519.22 million, a P/E ratio of -4.53 and a beta of 1.20. Stoke Therapeutics, Inc. has a fifty-two week low of $5.35 and a fifty-two week high of $17.58. The business's 50-day moving average price is $7.99 and its 200-day moving average price is $10.09.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.56) by $0.38. The company had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. Analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current fiscal year.

Analysts Set New Price Targets

STOK has been the subject of several recent analyst reports. Chardan Capital restated a "buy" rating and set a $24.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. HC Wainwright reaffirmed a "buy" rating and set a $47.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, April 9th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Stoke Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $25.60.

Insider Buying and Selling

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of the firm's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the sale, the insider now directly owns 63,962 shares in the company, valued at $554,550.54. This trade represents a 5.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Edward M. Md Kaye sold 10,382 shares of the company's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the transaction, the director now directly owns 148,253 shares of the company's stock, valued at approximately $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 16,532 shares of company stock valued at $143,332 in the last ninety days. Company insiders own 11.30% of the company's stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.